"instanceType","versionIdentifier","rationale","id","uuid:ID"
"StudyVersion","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","7696845b-52c4-461c-ae10-9b17ca2ea5f6"
